Article Information
History
- February 16, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Haolin Liu1,#,
- Pengcheng Wei1,
- Qianqian Zhang2,
- Zhongzhou Chen2,
- Katja Aviszus1,
- Walter Downing3,
- Shelley Peterson3,
- Lyndon Reynoso4,
- Gregory P. Downey5,
- Stephen K. Frankel5,
- John Kappler1,
- Philippa Marrack1,# and
- Gongyi Zhang1,#
- 1Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA
- 2State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agriculture University, Beijing 100193, People’s Republic of China
- 3Department of Nursing, National Jewish Health, Denver, CO80206, USA
- 4Department of Pharmacy, National Jewish Health, Denver, CO80206, USA
- 5Department of Medicine, National Jewish Health, Denver, CO 80206, USA
- ↵#Correspondents: Liuh{at}NJhealth.org, Marrackp{at}NJhealth.org, Zhangg{at}NJhealth.org
Posted February 16, 2021.
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
